

Title (en)
PHARMACEUTICAL COMPOUND

Title (de)
PHARMAZEUTISCHE ZUSAMMENSETZUNG

Title (fr)
COMPOSÉ PHARMACEUTIQUE

Publication
EP 3288967 A1 20180307 (EN)

Application
EP 16729054 A 20160428

Priority
• EP 15165537 A 20150428
• IB 2016052416 W 20160428

Abstract (en)
[origin: EP3088418A1] The present invention relates to an alpha-MSH analogue compound, the use in skin diseases, and the preparation.

IPC 8 full level
C07K 14/685 (2006.01)

CPC (source: EP KR US)
A61P 17/00 (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07K 7/06** (2013.01 - US);
C07K 14/685 (2013.01 - EP KR US); **A61K 38/00** (2013.01 - KR)

Citation (search report)
See references of WO 2016174610A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

DOCDB simple family (publication)
EP 3088418 A1 20161102; AU 2016255690 A1 20171207; AU 2016255690 B2 20200326; CA 2983980 A1 20161103;
DK 3288967 T3 20200210; EP 3288967 A1 20180307; EP 3288967 B1 20191106; ES 2769253 T3 20200625; JP 2018515600 A 20180614;
JP 6795258 B2 20201202; KR 20180002720 A 20180108; PH 12017501979 A1 20180326; PL 3288967 T3 20200518; PT 3288967 T 20200204;
SG 11201708818V A 20171129; SI 3288967 T1 20200430; US 2018086789 A1 20180329; WO 2016174610 A1 20161103

DOCDB simple family (application)
EP 15165537 A 20150428; AU 2016255690 A 20160428; CA 2983980 A 20160428; DK 16729054 T 20160428; EP 16729054 A 20160428;
ES 16729054 T 20160428; IB 2016052416 W 20160428; JP 2018507790 A 20160428; KR 20177034330 A 20160428;
PH 12017501979 A 20171027; PL 16729054 T 20160428; PT 16729054 T 20160428; SG 11201708818V A 20160428; SI 201630613 T 20160428;
US 201615569541 A 20160428